In a murine model of primary sclerosing cholangitis (PSC), localised delivery of IAld to the gut attenuated hepatic inflammation and fibrosis by modulating the gut microbiota and activating the AHR-IL−22 signalling axis, underscoring its therapeutic potential in gut-liver axis-related liver diseases.129. This evidence concerns the gene AHR and liver disorder.